GoingToMeet

Pharmacovigilance is becoming ever more critical for pharmaceutical companies as the public and legislative pressure to ensure drug safety increases every day. Effective implementation of pharmacovigilance can aid drug development, benefit rational communication and sound public understanding, taking emerging regulatory policies worldwide into account. The challenge to manage adverse events in an optimal and efficient way and, at the same time, adhere to regulatory requirements will demand a great emphasis on pharmacovigilance in the near future.

Key Speakers
• Dr Rachel Sobel, Senior Director, Epidemiology - Specialty Care BU Group Head, Pfizer
• Seema Jaitly, VP Global Medical & Scientific Affairs, Stiefel Laboratories, GSK
• Dr John Parkinson, Director, General Practice Research Database (GPRD), MHRA
• Dr John Talbot, Director - Patient Safety, Processes & Standards, AstraZeneca R&D
• Professor Saad Shakir, Director, Drug Safety Research Unit
• Dr Jacques Wodelet, Head of Quality Intelligence & Consultation, Merck-Serono, Geneva
• Dr Irene Michas, Director, Pharmacovigilance Education and Process Documentation (PEPD), Pfizer
• Paolo Biffignandi, Chief Medical Officer, EU Vigilance & President, TOPRA
• Dr James Weatherall, Global Lead, Biomedical Informatics, AstraZeneca
• Dr K N Woodward, Head - Global Pharmacovigilance, Intervet - Schering-Plough Animal Health